{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009642","form_type":"8-K","ticker":"MBX","cik":"0001776111","company_name":"MBX Biosciences, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.138673+00:00","generated_at":"2026-05-16T10:54:59.906946+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MBX Biosciences reports $373.7M cash, expands obesity pipeline with two new candidates in 2026","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities of $373.7M at Dec 31, 2025; runway into 2029.","Canvuparatide (HP): 1-year follow-up data from Phase 2 in Q2 2026; Phase 3 start on track for Q3 2026.","MBX 4291 (obesity, GLP-1/GIP prodrug): 12-week Phase 1 data expected Q4 2026; potential once-monthly dosing.","Two additional obesity candidates to be nominated in Q2 and Q3 2026: amycretin prodrug and GLP-1/GIP/GCGR triple agonist.","Imapextide (PBH): Phase 2a data in Q2 2026; once-weekly dosing preferred in patient surveys."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009642","json":"https://secwatch.observer/filing/0001193125-26-009642.json","markdown":"https://secwatch.observer/filing/0001193125-26-009642.md","text":"https://secwatch.observer/filing/0001193125-26-009642.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526009642/0001193125-26-009642-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526009642/mbx-20260111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:54:59.906946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}